Logo

Bayer to Acquire BlueRock Therapeutics for its Cell Therapies

Share this

Bayer to Acquire BlueRock Therapeutics for its Cell Therapies

Shots:

  • BlueRock to get $240M in cash as upfront and $360M as development milestones. In 2016- Bayer and Versant Ventures formed a joint venture establishing BlueRock Therapeutics- Bayer currently holds the 40.8% stock in BlueRock and will acquire the remaining stocks with its anticipated closure of transaction in Q3’19
  • The focus of the acquisition is to strengthen Bayer’s cell therapy portfolio with the addition of BlueRock’s CELL+GENE platform and cell therapies pipeline currently focusing on neurology- cardiology & immunology with the expected initiation of the clinical program in Parkinson’s disease in H2’19 and will operate as an independent company
  • BlueRock Therapeutics’ CELL+GENE platform includes a broad intellectual property portfolio and technology platforms including iPSC technology- gene engineering and cell differentiation capabilities and harvests primary cells to develop therapies

Click here to­ read full press release/ article | Ref: Bayer | Image: Bloomberg


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions